AFP、AFU联合β_2-MG在原发性肝癌诊断中的价值

Diagnostic value of combined detection of AFP,AFU and β_2-MG in primary hepatocellular carcinoma

目的探讨联合检测甲胎蛋白(AFP)、α-L-岩藻糖苷酶(AFU)及#2-微球蛋白(#2-MG)在原发性肝癌诊断中的价值。方法分别采用电化学发光法、速率法和免疫透射比浊法检测78例原发性肝癌患者、45例肝硬化患者及50例健康者血清中AFP、AFU和#2-MG的含量。结果 AFP、AFU和#2-MG在原发性肝癌患者血清中的浓度均高于肝硬化组及正常对照组(P<0.01),且原发性肝癌组中的AFP、AFU和#2-MG阳性率高于肝硬化组的阳性率,AFP、AFU和#2-MG三项指标联合检测阳性率明显高于各指标单独检测的阳性率(P<0.01)。结论 AFP、AFU和#2-MG联合检测可显著提高原发性肝癌诊断的阳性率,对原发性肝癌的早期诊断和及时治疗具有重要的临床应用价值。

Objective To study the diagnostic value of combined detection of AFP, AFU and β2 - MG in primary hepatocellu- lar carcinoma（PHC）. Methods The serum AFP, AFU and β2 - MG levels in 78 PHC patients, 45 liver cirrhosis patients and 50 healthy controls were detected by the electrochemical luminescence method, rate method and immune turbidimetry, respec- tively. Results The serum levels of AFP, AFU and β2 - MG in PHC patients were all significantly higher than those in liver cirrhosis patients and healthy controls （P 〈 0.01 ）. The positive rates of AFP, AFU and β2 - MG in PHC group were also higher than those in liver cirrhosis group. Moreover, the positive rate of combined determination of the three biomarkers was significantly higher than that of any single biomarker（P 〈0. O1 ）. Conclusion The combined detection of AFP, AFU and β2 - MG can improve the positive rate in diagnosis of primary hepatocellular carcinoma, and has significant clinical values in the early diagnosis and treatment of primary hepatocellular carcinoma.